120 related articles for article (PubMed ID: 19062528)
1. [Monogenic hypercholesterolemias: new genes, new drug targets].
Mandel'shtam MIu; Vasil'ev VB
Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528
[TBL] [Abstract][Full Text] [Related]
2. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
3. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
4. Targeting PCSK9 for the treatment of hypercholesterolemia.
Hedrick JA
Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
6. Unravelling the functional significance of PCSK9.
Lambert G
Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Costet P; Krempf M; Cariou B
Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
[TBL] [Abstract][Full Text] [Related]
8. PCSK9: an emerging target for treatment of hypercholesterolemia.
Duff CJ; Hooper NM
Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of PCSK9 function.
Lambert G; Charlton F; Rye KA; Piper DE
Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Maxwell KN; Breslow JL
Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
[TBL] [Abstract][Full Text] [Related]
11. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
12. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
[TBL] [Abstract][Full Text] [Related]
13. Molecular biology of PCSK9: its role in LDL metabolism.
Horton JD; Cohen JC; Hobbs HH
Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
[TBL] [Abstract][Full Text] [Related]
14. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.
Mousavi SA; Berge KE; Leren TP
J Intern Med; 2009 Dec; 266(6):507-19. PubMed ID: 19930098
[TBL] [Abstract][Full Text] [Related]
15. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
[TBL] [Abstract][Full Text] [Related]
16. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
Leren TP
Clin Genet; 2004 May; 65(5):419-22. PubMed ID: 15099351
[TBL] [Abstract][Full Text] [Related]
18. Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
Mbikay M; Mayne J; Seidah NG; Chrétien M
Med Hypotheses; 2007; 69(5):1010-7. PubMed ID: 17502126
[TBL] [Abstract][Full Text] [Related]
19. [Familial hypercholesterolemia in Tunisia].
Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]